Court Clears Teva After At-Risk Budesonide Entry

 
• By Aidan Fry
  
RiskReward
Teva has seen its decision to launch generic budesonide extended-release tablets 'at risk' in the US pay off • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin